Sotatercept for Pulmonary Hypertension
Recruiting0 awardsPhase 2
Kansas City, Kansas
This trial tests sotatercept, a medication aimed at improving heart and lung function in adults with a specific type of heart failure. It works by reducing resistance in lung blood vessels, helping the heart pump blood more easily.
Biguanide
Metformin for Pulmonary Hypertension
Recruiting0 awardsPhase 2
San Francisco, California
This trial is testing whether the diabetes drug metformin can improve outcomes in people with PH-HFpEF. The study will look at how well metformin works compared to placebo and what the effects are on heart function and capacity.
Behavioral Intervention
Exercise Program for Pediatric Pulmonary Hypertension
Recruiting1 award
Philadelphia, Pennsylvania
"This trial aims to help children and teenagers with pulmonary hypertension (PH) be more active and improve their muscle strength. Previous studies have shown that children with PH are less active and have weaker muscles compared to
Popular Filters
Trials for Pulmonary Arterial Hypertension Patients
Prostacyclin Receptor Agonist
Ralinepag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Trials for PAH Patients
Prostacyclin Receptor Agonist
Ralinepag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Phase 3 Trials
Prostacyclin Receptor Agonist
Ralinepag for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Endothelin Receptor Antagonist
High-Dose Macitentan for PAH
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Trials With No Placebo
Prostacyclin Analogue
Inhaled Treprostinil for Sarcoidosis
Recruiting1 awardPhase 2
Gainesville, Florida
This trial is testing an inhaled medication called treprostinil for people with a specific lung disease (sarcoidosis) that causes high blood pressure in the lungs. The treatment aims to help these patients breathe better and exercise more easily by widening their lung blood vessels. The study will also check if this treatment is safe for them. Inhaled treprostinil has been shown to improve exercise tolerance and has demonstrated safety and beneficial effects on hemodynamics, exercise capacity, and quality of life.
Computerized Decision Support for Pulmonary Hypertension
Recruiting1 award5 criteria
Boston, Massachusetts
This trial will test whether or not an electronic health record alert will increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in patients with prior pulmonary embolism and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms.
Procedure
Pulmonary Artery Denervation for Pulmonary Hypertension
Recruiting1 award6 criteria
San Diego, California
This trial is testing a new system to treat PH by denerving, or cutting, the pulmonary arteries. The study will follow patients to see if this improves their symptoms, including how far they can walk, their quality of life, and how their heart is functioning.
Procedure
Denervation System for Heart Failure and Pulmonary Hypertension
Recruiting1 award
Durham, North Carolina
This trial tests a new procedure called PADN that reduces nerve activity in lung arteries. It aims to help heart failure patients with pulmonary hypertension, who currently have no other treatments. By calming these nerves, it may lower lung blood pressure and improve heart function. Pulmonary artery denervation (PADN) has been clinically shown to be effective in controlling pulmonary hypertension.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.